
    
      This was a pilot, phase II, double-blind, randomized, muticenter, active-comparator, five
      treatment parallel group dosing and mechanistic study. The study consisted of two phases: 1)
      screen/washout/single-blind placebo run-in and 2) randomization/treatment. There was a
      minimum of five scheduled study visits.
    
  